Metadata
Dataset ID:
17
Study Design
Study Design Background | The study provides evidence that SYRO plus MET has a synergistic effect on tumor growth inhibition in both 4T1 and TS/A experimental models |
---|---|
Study Description | SYRO plus MET, this radiotracer could be potentially used as a biomarker for the early detection of therapy response |
Study Type | preclinical |
Study Subtype | in vivo, ex vivo |
Publication
Paper Linked | yes |
---|---|
Paper Title | Evaluating [18F]FDG and [18F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer models |
Paper Authors | Rainone P, Valtorta S, Villa C, Todde S, Cadamuro M, Bertoli G, Conconi D, Lavitrano M, Moresco RM |
Affiliation | University of Milano - Bicocca |
Paper Journal | International Journal of Molecular Sciences |
Paper Year | 2023 |
Paper Doi | https://doi.org/10.3390/ijms241814124 |
Open Access | yes |
Updated Year | 2024 |
Study Component
Multi Modality Images | yes |
---|---|
Imaging Modality | PET/CT |
Radiation | yes |
Imaging Coverage | whole body |
Imaging Target | tumor |
Dataset Information
Institution | IBSBC-CNR |
---|---|
Pi | Prof. Moresco Rosa Maria |
Country Of Institution | Italy |
Imaging Facility | Laboratory of preclinical molecular imaging |
Euro Bio Imaging Node | MMMI |
Country Of Imaging Facility | Italy |
Funding | yes |
Funding Agency | MOLIM ONCOBRAIN LAB—Innovative methods of molecular imaging for the study of oncological and neurodegenerative diseases, AIRC |
Grant Number | 2017-NAZ-0146/A, grant n.21635 |
Dataset Access | limited |
Duo Data Use Permission | DUO:0000042 |
Duo Data Use Modifier | DUO:0000046 |
Duo Investigation | DUO:0000040 |
Contact Person | paolo.rainone@unimib.it |
In Vivo Experimental Parameters
Number Of Groups | 6 |
---|---|
Types Of Groups | control, cisplatin, MET, cisplatin plus MET, SYRO, and SYRO plus MET |
Overall Sample Size | 57 |
Disease Model | breast cancer |
Organ Or Tissue | mammary gland |
Sample Size For Each Group | 5 o 4 |
Randomization | yes, when tumors were palpable, the animals inoculated with 4T1 or TS/A were randomly assigned |
Blinding | no |
Statistical Methods | Student’s t-test |
Species | Mice |
Strain | Balb/c |
Immune Status | immunecompetent |
Sex | female |
Age | 7-8 weeks |
Age At Start Experiment | 8 weeks |
Age At Scanning Experiment S | 56 and 63 days |
Weight | 24-26 g |
Genotype | n/a |
Genetic Manipulation | n/a |
Gene | n/a |
Source Of Animals | Charles River Laboratories, Italy |
Experimental Procedures
Pharmacological Procedures Intervention And Control | yes |
---|---|
Pharmacological Drug | metformin, syrosingopine, cisplatin |
Company | Sigma Aldrich |
Drug Dose | MET 250 mg/kg, SYRO 7.5 mg/kg, cisplatin 3 mg/kg |
Site Route Of Administration | intraperitoneal |
Frequency Of Administration | MET daily, SYRO three times for week, cisplatin twice a week |
Vehicle Or Carrier Solution Formulation | All drugs dissolved in saline, except SYRO that was dissolved in DMSO (10% in sterile water) |
Blood Sampling | no |
Surgical Procedures Including Sham Surgery | no |
Pathogen Infection Intervention And Control | no |
Analgesic Plan To Relieve Pain Suffering And Distress | no |
Anesthesia For Imaging | yes |
Anesthesia Type | gas |
Duration | 20 |
Anesthesia Drugs | isoflurane |
Anesthesia Dose | 2% |
Euthanasia | yes |
Method | anesthesia |
Histology | yes |
Tissues Collected Post Euthanasia | tumor |
Timing Of Collection | end of study |
Imaging | yes |
Frequency Of Imaging | Single scan |
Timing Of Imaging | t0 and after 7 days of the treatment |
Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule | yes |
Contrast Agent Commercial Drug | [18F]FDG, [18F]FLT |
Contrast Agent Chemical Drug | 18F-fluorodeoxyglucose (FDG), 18F-fluorothymidine (FLT) |
Contrast Agent Dose | 4.67 ± 0.3 MBq |
Injection Volume | 0.05 - 0.1 ml |
Route Of Administration | intravenous |
Cell Lines | yes |
Cell Line | 4T1, TS/A |
Provenance | TS/A (Sigma-Aldrich Inc., St. Louis, MO, USA), 4T1 (ATCC) |
Image Acquisition
Instrument Vendor | Molecubes |
---|---|
Instrument Type | β-cube, X-cube |
Instrument Specifics | FOV size for PET 130X72 mm, FOV size for CT 37X65 mm |
Image Acquisition Parameters | CT scan (exam duration: 4 min, X-Ray beam duration: 90 s, kVp: 40, current:400 A, rotation time: 60 s, and angular views: 960), PET scanner for a 20 min static acquisition |
Correction | decay correction (PET) |
Raw Data | yes |
Image Correlation
Image Type | Processed images (reconstructed PET and CT data) |
---|---|
Image Scale | SUV for PET |
Format Compression | DICOM |
Dimensions | 3D |
Overall Number Of Images | 36 |
Field Of View | Abdominal |
Dimension Extents | 192x192x384 |
Pixel Voxel Size Description | 0.4x0.4x0.4 |
Image Processing Methods | Image reconstruction |
Image Reconstruction Algorithm | OSEM |
Quality Control | n/a |
Image Smoothing Or Filtering Algorithm | n/a |
Image Registration Algorithm | n/a |
Ai Enhanced Algorithm | yes |
Analyzed Data
Data Used For Analysis | SUV, volume measurements |
---|---|
Status | complete |
Ontology Terms
Ncit Imaging | NCIT:C103512 |
---|---|
Doid | DOID:1612 |
Ncit Anatomy | NCIT:C12367 |
Ncit Species | NCIT:C14238 |
Ncit Strain | NCIT:C37357 |
Chebi Pharmaco | CHEBI:6801,CHEBI:32175,CHEBI:27899 |
Chebi Anesthesia | CHEBI:6015 |
Chebi Contrast Agent Commercial Name | CHEBI:49134,NCIT:C49093 |
Chebi Contrast Agent Chemical Name | CHEBI:49134,NCIT:C49093 |
Clo | CLO:0001401,CLO:0009405 |